EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Spinal mechanisms and feasibility of Dry Needling versus Botulinum Toxin Type A in post-stroke lower limb spasticity: A proof-of-concept randomized clinical trial protocol (STROKE-POC)

Clara Pujol-Fuentes iD, Bart Eeckhaut iD, Samuel Fernández Carnero iD, Daniel Fernández Sanchís, Theodore Wein, Pablo Herrero iD, Wim Saeys iD, Mindy F Levin

PLOS One · 20.05.2026 · 21 (5) · e0334571

DOI: 10.1371/journal.pone.0334571 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 20.05.2026. Verfasst von Clara Pujol-Fuentes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health and Sciences, Department of Physiotherapy, Universidad Europea de Valencia‌‌, Valencia, Spain. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Dry Needling, Lower Extremity, Muscle Spasticity. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Institute of Innovation and Technology, Instituto de Salud Carlos III, Fonds de Recherche du Québec - Santé.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Stroke often causes spasticity, impacting mobility and quality of life. Botulinum Toxin type A (BTX-A) and Dry Needling (DN) are treatments that reduce spasticity, although Botulinum Toxin type A injections can cause adverse effects. No studies have directly compared their effects at spinal, muscular, functional, quality-of-life, and cost-effectiveness levels. This study aims to determine the spinal mechanisms of BTX-A and DN on post-stroke lower limb spasticity, while also assessing feasibility, safety, and exploratory effects at muscular, functional, quality-of-life, and cost-effectiveness levels. Methods and analysis This is a protocol of a proof-of-concept, feasibility randomized clinical trial including 90 participants from Canada, Belgium, and Spain who experienced a first stroke in the previous 12 months and present plantar flexor spasticity. Time since stroke (0–12 months) will be recorded and explored as a potential modifier of treatment response. Participants will be randomly assigned to receive either one session of BTX-A or 12 weekly sessions of DN. Blinded evaluators will assess outcomes before, during, and after treatment, with a 4-week follow-up. The primary outcome will be spinal mechanisms of spasticity, measured using the Tonic Stretch Reflex Threshold and its velocity sensitivity. Secondary outcomes will assess: a) muscular architecture and echotexture (measured with ultrasound); b) muscle tone/resistance using the Modified Ashworth Scale; c) gait and mobility (instrumented analysis, Timed Up and Go, 10-Meter Walk Test); d) muscle strength with dynamometry; e) quality of life with the EuroQoL questionnaire; and f) cost-effectiveness (analytic model). The findings will provide preliminary data to inform a future definitive trial. Ethics and Dissemination This research project has secured funding from the NEURON ERA-NET 2022 call, supported by the European Union’s Horizon 2020 program (GA 964215) and co-funded by the European Union-Next Generation, and has undergone peer review. Ethical approval has been obtained from Spain, Canada, and Belgium. The study is registered in ClinicalTrials.gov (NCT06296082) and the Clinical Trials Information System (CTIS) under the number 2024-510866-18-00. The study protocol is registered on Zenodo ( https://doi.org/10.5281/zenodo.20034064 ) Clinical Trials Clinical Trials NCT06296082; https://clinicaltrials.gov/study/NCT06296082

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ADry NeedlingLower ExtremityMuscle SpasticityStrokeAdultFemaleHumansMaleMiddle AgedCost-Benefit AnalysisFeasibility StudiesProof of Concept StudyQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeClinical Trials, Phase II as TopicMulticenter Studies as TopicClinical Trials, Phase III as Topic

Substanzen

Botulinum Toxins, Type A

Autor:innen und Institutionen

  • Faculty of Health and Sciences, Department of Physiotherapy, Universidad Europea de Valencia‌‌, Valencia, Spain.
  • Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain.
  • Faculty of Health Sciences and Medicine, Department of Rehabilitation Sciences and Physiotherapy‌‌, University of Antwerp, Antwerp, Belgium.
  • Universidad de Alcalá, Facultad de Medicina y Ciencias de la Salud, Departamento de Enfermería y Fisioterapia, Grupo de Investigación Fisioterapia y Dolor, Alcalá de Henares, Spain.
  • Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego, Zaragoza, Spain.
  • Faculty of Medicine, Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

ORCID-Profile: Clara Pujol-Fuentes, Bart Eeckhaut, Samuel Fernández Carnero, Pablo Herrero, Wim Saeys

Förderung

  • H2020 European Institute of Innovation and Technology
  • Instituto de Salud Carlos III
  • Fonds de Recherche du Québec - Santé
  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Pujol-Fuentes, C., Eeckhaut, B., Fernández Carnero, S., Fernández Sanchís, D., Wein, T., Herrero, P., Saeys, W., & Levin, M. F. (2026). Spinal mechanisms and feasibility of Dry Needling versus Botulinum Toxin Type A in post-stroke lower limb spasticity: A proof-of-concept randomized clinical trial protocol (STROKE-POC). PLOS One, 21(5), e0334571. https://doi.org/10.1371/journal.pone.0334571

Vancouver

Pujol-Fuentes C, Eeckhaut B, Fernández Carnero S, Fernández Sanchís D, Wein T, Herrero P, et al. Spinal mechanisms and feasibility of Dry Needling versus Botulinum Toxin Type A in post-stroke lower limb spasticity: A proof-of-concept randomized clinical trial protocol (STROKE-POC). PLOS One. 2026;21(5):e0334571. doi:10.1371/journal.pone.0334571

BibTeX
@article{PujolFuentes2026,
  author = {Pujol-Fuentes, Clara and Eeckhaut, Bart and Fernández Carnero, Samuel and Fernández Sanchís, Daniel and Wein, Theodore and Herrero, Pablo and Saeys, Wim and Levin, Mindy F},
  title = {Spinal mechanisms and feasibility of Dry Needling versus Botulinum Toxin Type A in post-stroke lower limb spasticity: A proof-of-concept randomized clinical trial protocol (STROKE-POC)},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {5},
  pages = {e0334571},
  doi = {10.1371/journal.pone.0334571}
}
Kostenlos starten →